Publication | Open Access

Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States

MedicinePharmacologyMetastatic NsclcImmune Checkpoint InhibitorPharmacotherapyCost EffectivenessCancer TreatmentOncologyUnited StatesLung Cancer